Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Advanced or Metastatic ER+ Breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 15 of 0 results

Early research (Phase 1)WithdrawnNCT02567396
What this trial is testing

Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery and Liver or Kidney Dysfunction

Who this might be right for
Estrogen Receptor NegativeHead and Neck Squamous Cell CarcinomaHER2/Neu Negative+20 more
National Cancer Institute (NCI)
Large-scale testing (Phase 3)Study completedNCT03096847
What this trial is testing

Study for Women and Men With Hormone-receptor Positive Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Advanced Metastatic Breast Cancer
Novartis Pharmaceuticals 502
Early research (Phase 1)Study completedNCT02684032
What this trial is testing

Assess The Tolerability And Clinical Activity Of Gedatolisib In Combination With Palbociclib/Letrozole Or Palbociclib/Fulvestrant In Women With Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Celcuity Inc 141
Testing effectiveness (Phase 2)Study completedNCT00755885
What this trial is testing

Abiraterone Acetate in Treating Postmenopausal Women With Advanced or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Cancer Research UK 77
Testing effectiveness (Phase 2)Looking for participantsNCT07002177
What this trial is testing

A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC

Who this might be right for
Metastatic Breast CancerBreast Cancer Stage IBreast Cancer Stage II+2 more
Forward Pharmaceuticals Co., Ltd. 196
Large-scale testing (Phase 3)Study completedNCT03176238
What this trial is testing

Study in Post-menopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer

Who this might be right for
Post Menopausal Breast Cancer
Novartis Pharmaceuticals 235
Early research (Phase 1)Active Not RecruitingNCT05293964
What this trial is testing

Phase I Study to Evaluate SIM0270 Alone or in Combination in ER+, HER2- Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Jiangsu Simcere Pharmaceutical Co., Ltd. 214
Testing effectiveness (Phase 2)Ended earlyNCT05618613
What this trial is testing

Study of Elacestrant in Combination With Onapristone in Patients With Advanced or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Context Therapeutics Inc. 4
Early research (Phase 1)Ended earlyNCT05080842
What this trial is testing

AC682 for the Treatment of Locally Advanced or Metastatic ER+ Breast Cancer

Who this might be right for
Breast Cancer
Accutar Biotechnology Inc 21
Testing effectiveness (Phase 2)Looking for participantsNCT07100106
What this trial is testing

Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer

Who this might be right for
Breast Cancer
Genentech, Inc. 285
Testing effectiveness (Phase 2)Study completedNCT02049957
What this trial is testing

Safety and Efficacy Study of Sapanisertib in Combination With Exemestane or Fulvestrant in Postmenopausal Women With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Calithera Biosciences, Inc 118
Testing effectiveness (Phase 2)Ended earlyNCT02569801
What this trial is testing

GDC-0810 Versus Fulvestrant in Postmenopausal Women With Advanced or Metastatic Breast Cancer Resistant to Aromatase Inhibitor (AI) Therapy

Who this might be right for
Breast Cancer
Genentech, Inc. 71
Early research (Phase 1)Study completedNCT00031681
What this trial is testing

7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)

Who this might be right for
Advanced Adult Primary Liver CancerCarcinoma of the AppendixEstrogen Receptor-negative Breast Cancer+85 more
National Cancer Institute (NCI) 41
Testing effectiveness (Phase 2)Looking for participantsNCT06395519
What this trial is testing

PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies

Who this might be right for
Advanced or Metastatic Solid TumorsBreast CancerOvarian Cancer+10 more
858 Therapeutics, Inc. 120
Testing effectiveness (Phase 2)UnknownNCT03044730
What this trial is testing

Pembrolizumab and Capecitabine in Treating Patients With Locally Advanced or Metastatic Triple Negative or Hormone-Refractory Breast Cancer That Cannot Be Removed by Surgery

Who this might be right for
Estrogen Receptor NegativeHER2/Neu NegativeProgesterone Receptor Negative+7 more
Northwestern University 30